Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response
about
Alemtuzumab for B-cell chronic lymphocytic leukemia.Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying DiseaseTreating multiple sclerosis with monoclonal antibodies.Alemtuzumab in the treatment of chronic lymphocytic lymphoma.Pharmacokinetics of alemtuzumab and the relevance in clinical practice.Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Pediatric Dosing and Body Size in Biotherapeutics.Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?A guide to rational dosing of monoclonal antibodies.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Preclinical development of therapeutic biologics.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Drug Development of Therapeutic Monoclonal Antibodies.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.A cell-level model of pharmacodynamics-mediated drug disposition.Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation.Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study.Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients.Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological AgentsBasic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsAlemtuzumab in allogeneic hematopoetic stem cell transplantation.Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.The outlook for alemtuzumab in multiple sclerosis.Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.
P2860
Q33380135-BC2AFDFF-C21D-4696-968D-C0CD3C4144E6Q33708140-FD9A9B53-E01F-49EC-BBFA-B49B4F5A3A33Q33956034-89962F6A-1A7E-4DC7-A23A-002AB12AF75EQ34209556-DA8D8906-555A-494B-815F-326114F51857Q35061729-A65E7AB5-697A-46DD-A632-C2169D405E84Q35929084-50594F84-CB87-47D4-851C-1617ED536CC7Q36156205-3B76BDB1-1AA5-415D-97D4-C562164ED8E2Q37111904-30ED05BF-1FCC-4B8E-8F55-85467C462F88Q37134417-48CC8AB6-9061-44FA-B20C-C3FE9350AE37Q37340406-953151B2-5E27-4C3B-AFD9-3407F8AF12FDQ37510861-B5AC0C71-2400-47E5-A5D4-70A155AA5FDCQ37666711-8C06F596-58F9-4BF6-AA3A-EA23F604F79CQ37810989-C96EEC4C-36CF-43A7-BD73-8F5E8EF670C2Q37976121-57B30498-089E-47EB-B4FC-C60A6E9E8567Q37976878-1FC90FBB-73B6-4556-8316-1861B316B449Q38072598-27D06A7D-2A2C-4F81-B985-C58B1BEA89E7Q38088310-AAB57F86-EE0C-4847-B597-7713D89845BFQ38204975-6173F6FC-A6DB-4BE5-86FD-BC31F34CB111Q38262916-FD8C9E40-F0B2-441F-86EA-7FF406854825Q38364464-C91B74F2-F5F8-49F8-B571-00D479204065Q38372455-2AC2355E-66D8-48D5-8E37-6A0D0A253ED4Q38564877-DF68AF41-ABAC-4EEA-A8A7-CC8174FB38DFQ38714339-89B0B7FE-8C02-46D1-A6FC-61BA2C8D403DQ38876360-8ECEAC66-6257-44ED-B672-5DD8DD145173Q38962519-E0555680-D342-44A3-9C31-AD1A638BA21FQ38987211-45817C17-21EC-4E4E-B558-D286E95045C5Q39406092-C63BD816-AEB0-49F7-AEEE-C38BEDB34480Q39409394-C7201B4E-788F-420F-A5E1-DBE2099B4F6AQ39544646-7B08B6F4-1990-4194-9FD4-30477F298C0EQ40217347-709B8C2A-B69C-49D5-9789-9CE563F10682Q40270917-B02739B1-C6F9-4AF2-8ED3-CCB1076E045DQ41198127-813EB639-9A8D-4EE5-A9BC-F5B3294A8C52Q41775229-0FB36F26-1E7C-4CCF-923E-399C6B904C5AQ42149544-589FAED4-FA5B-481A-B688-7D07F5E3CDC8Q42728350-FF425821-4650-4918-A645-E243E6E47EE8Q42743059-2AEFD5CE-5982-45B6-8872-0A031180BFA2Q43482708-CDDD9912-C2B3-43FC-8395-9068B3C125C4Q45916399-7709BC9E-1957-4B70-A63A-FBE1F6279BD5Q46866013-B9D8FD5E-FED3-411E-9840-03C39B12C9BCQ47176287-7DE9A5ED-F36F-4D57-97CC-09FBB569791D
P2860
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Population pharmacokinetics-ph ...... its link to treatment response
@ast
Population pharmacokinetics-ph ...... its link to treatment response
@en
type
label
Population pharmacokinetics-ph ...... its link to treatment response
@ast
Population pharmacokinetics-ph ...... its link to treatment response
@en
prefLabel
Population pharmacokinetics-ph ...... its link to treatment response
@ast
Population pharmacokinetics-ph ...... its link to treatment response
@en
P2093
P2860
P1476
Population pharmacokinetics-ph ...... its link to treatment response
@en
P2093
J Kuhlmann
L R Brettman
M J Keating
P L Bonate
P2860
P304
P356
10.1111/J.1365-2125.2007.02914.X
P407
P577
2007-05-16T00:00:00Z